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Abstract
The Plasmodium falciparum lactate dehydrogenase enzyme (PfLDH) has been considered as a potential molecular target for
antimalarials due to this parasite’s dependence on glycolysis for energy production. Because the LDH enzymes found in P.
vivax, P. malariae and P. ovale (pLDH) all exhibit ,90% identity to PfLDH, it would be desirable to have new anti-pLDH
drugs, particularly ones that are effective against P. falciparum, the most virulent species of human malaria. Our present
work used docking studies to select potential inhibitors of pLDH, which were then tested for antimalarial activity against P.
falciparum in vitro and P. berghei malaria in mice. A virtual screening in DrugBank for analogs of NADH (an essential cofactor
to pLDH) and computational studies were undertaken, and the potential binding of the selected compounds to the PfLDH
active site was analyzed using Molegro Virtual Docker software. Fifty compounds were selected based on their similarity to
NADH. The compounds with the best binding energies (itraconazole, atorvastatin and posaconazole) were tested against P.
falciparum chloroquine-resistant blood parasites. All three compounds proved to be active in two immunoenzymatic assays
performed in parallel using monoclonals specific to PfLDH or a histidine rich protein (HRP2). The IC50 values for each drug in
both tests were similar, were lowest for posaconazole (,5 mM) and were 40- and 100-fold less active than chloroquine. The
compounds reduced P. berghei parasitemia in treated mice, in comparison to untreated controls; itraconazole was the least
active compound. The results of these activity trials confirmed that molecular docking studies are an important strategy for
discovering new antimalarial drugs. This approach is more practical and less expensive than discovering novel compounds
that require studies on human toxicology, since these compounds are already commercially available and thus approved for
human use.
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Introduction
Malaria is the most lethal parasitic disease in the world,
annually affecting approximately 500 million people and resulting
in 800,000 deaths, mostly in African sub-Saharan countries [1].
Brazil registered 306,000 cases of malaria in 2009, most of which
were in the Amazonian region, as diagnosed and treated by
Ministry of Health officers [2], [3]. Transmission occurs through
the bite of Anopheles mosquitoes infected with the parasite and five
different species may affect humans. Plasmodium falciparum is the
most pathogenic species and may cause severe malaria and death
in untreated nonimmune individuals, especially children under
five [4].
The antimalarial treatment recommended for P. falciparum
consists of drug combinations containing artemisinin derivatives
(ACT) with other antimalarials, including quinoline compounds,
such as amodiaquine and mefloquine. The quinolines act mainly
by inhibiting hematin polymerization, thus intoxicating the
parasite with the ferriprotoporphyrinic groups generated by
hemoglobin degradation [5]. Other antimalarials used in ACT,
for example, pyrimethamine and proguanil, inhibit the tetrahy-
drofolic acid cycle and thus eliminate an important cofactor for
DNA synthesis. Despite the arsenal of drugs available for malaria
treatment, the disease remains a worldwide public health problem.
P. falciparum quickly develops resistance under selective drug
pressure [5]. P. vivax, the most prevalent human parasite
worldwide, has been shown to be resistant to chloroquine,
including in Brazil [3]. Continuous efforts on the development
of new antimalarials are required, and our primary method has
been to use different approaches, such as testing natural products
and synthetic molecules, as reviewed [6], [7].
Drug-resistant malaria parasites are believed to emerge through
mutations in the active sites of drug targets [5] or from
biochemical changes in the drug receptors [8]. The continued
search for new molecular targets for drug design should broaden
the therapeutic arsenal and strategies to fight drug resistance in
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falciparum (PfLDH) has been considered as a potential molecular
drug target. Although the primary mechanism of action of
quinoline drugs is by inhibition of heme polymerization [9], other
molecular targets have been reported as being important for the
improvement of their biological effectiveness against P. falciparum.
Chloroquine interacts specifically with PfLDH in the NADH
binding pocket, occupying a position similar to that of the adenyl
ring cofactor and hence acting as a competitive inhibitor for this
critical glycolytic enzyme [9], [10], [11], [12].
The LDH enzyme catalyzes the interconversion of pyruvate to
lactate in the final step of glycolysis, which is required for energy
production in living cells. Ferriprotoporphyrin IX (hematin), one
of the products of hemoglobin degradation by malarial parasites,
intoxicates the parasite by competing with NADH for the active
site of PfLDH; parasite survival depends on polymerization of
hematin to hemozoin, which remains active in the food vacuole of
the parasite and causes parasite death [9]. The quinoline
derivatives are believed to form complexes with the dimeric
hematin, preventing the formation of hemozoin [11].
Analogs of NADH have been identified as new potential
inhibitors to PfLDH in DrugBank [13]. In previous docking
studies, Molegro Virtual Docker software (MVD)H yielded higher
docking accuracy than other docking programs; the accuracies
were: MVD, 87%; Glide, 82%; Surflex, 75%; and FlexX, 58%
[14]. A total of 50 compounds were selected based on their
interactions with an active site similar to that of NADH; the three
(itraconazole, atorvastatin and posaconazole) compounds that
presented the best theoretical results were tested in vitro against P.
falciparum blood parasites and against malaria in mice.
Results
Docking studies
The results of docking studies using the MolDock Scores
observed for NADH and the 50 compounds chosen from the
DrugBank [13] are summarized in Table 1. The superposition of
NADH, as observed in the cavity of the crystallographic structure
of PfLDH, and the best conformation obtained theoretically for
itraconazole are shown in Figure 1. This result suggests that the
software reproduced the appropriate conformation of NADH
inside its binding pocket in the PfLDH active site.
The compounds atorvastatin and posaconazole also fitted well
in the NADH pocket (data not shown), showing the best docking
energy values, that is, closest to NADH (which has a docking
energy of 2249.6 kcal?mol
21). These three compounds were
selected for further in vitro tests because they are commercially
available for human use as well.
The active site residues that interact with NADH, itraconazole,
atorvastatin and posaconazole inside PfLDH are shown in Table 2,
and the H-bonds between each compound and the PfLDH active
site are shown in Figures 2 and 3. The H-bond energy values were
21.9 kcal?mol
21, 25.0 kcal?mol
21 and 26.5 kcal?mol
21 for
atorvastatin, itraconazole and posaconazole, respectively, and
are all higher than that observed for NADH, which is able to make
more H-bonds in the binding pocket than the studied compounds.
Activity of itraconazole, atorvastatin and posaconazole
against P. falciparum
The in vitro tests against chloroquine-resistant P. falciparum clone
W2 showed that itraconazole, atorvastatin and posaconazole were
active. In two different immunoenzymatic assays (ELISA) with
monoclonals anti-PfLDH or anti-HRP2, the three compounds
inhibited parasite growth at low doses. Posaconazole was the most
Figure 1. Superposition of the best conformation of itracon-
azole (in yellow) and NADH (in red) in the active site pocket of
P. falciparum enzyme lactate dehydrogenase (Pf LDH).
doi:10.1371/journal.pone.0021237.g001
Table 1. MolDock Scores observed for NADH and the 50
compounds chosen from the DrugBank [13].
Drugs
MolDock Score
(kcal.mol
21) Drugs
MolDock Score
(kcal.mol
21)
NADH 2249.6 Cefotaxime 2143.2
Itraconazole 2218.5 Valaciclovin 2142.4
Atorvastatin 2209.3 AMP 2136.5
Posaconazole 2201.6 Cephapirin 2136.5
Rescinnamine 2201.0 Cefuroxime 2135.2
Cefpiramide 2195.0 Cefalotin 2132.9
Eprosartan 2177.0 Abacavir 2130.4
Cefditoren 2177.2 Entecavir 2130.4
Ergotamine 2175.0 Capecitabine 2129.1
Cefmenoxime 2173.3 Topotecan 2128.6
Dicloxacilin 2165.0 Tenoxican 2123.9
Novobiocin 2162.5 Genifloxacin 2120.6
Ceftriaxone 2157.4 Cefdinir 2117.2
Cefamandole 2154.9 Moxifloxacin 2116.4
Ceftazidine 2156.8 Clorafabine 2114.8
ATP 2155.2 Adenosine 2113.6
Cefamandole 2154.9 Zidovudine 2111.7
Dasatinib 2154.5 Nelarabine 2111.3
Droperidol 2152.3 Cladribine 2111.0
Cefixime 2151.0 Pentostanine 2110.7
S-Adenozylmetionine 2150.7 Vidarabine 2110.6
Paliperidol 2150.4 Trifluridine 2102.2
Rysperidone 2146.9 Zalcitabine 294.4
Cefmetazole 2146.9 Gemcitabine 292.1
Bethamidine 2144.3 Floxuridine 291.4
doi:10.1371/journal.pone.0021237.t001
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IC50 was 2.6 mM in the ELISA anti-PfLDH; the average of IC50
from the experiments is shown in Table 3, corroborating our
computer analysis and docking calculations (Table 1).
Antimalarial tests in mice with malaria due to P. berghei
The compounds active in vitro were next tested in mice infected
with P. berghei. Due to limitations in the availability of the purified
compounds, they were first tested at doses of 20 mg/kg. All
compounds inhibited parasite growth, especially atorvastatin and
posaconazole, which reduced parasitemia by 41% and 46%,
respectively, compared to untreated group (Table 4). Further tests
confirmed the activity of atorvastatin (data not shown) and
posaconazole. For the latter, a commercially available oral
suspension of posaconazole, formulated for human use (NoxafilH)
was acquired at a pharmacy in the USA and tested at 50 and
100 mg/kg. It reduced parasitemia in the treated mice by 45%
and 71%, respectively, as compared to untreated controls
(Table 4).
However, itraconazole reduced parasitemia by only 30%
whereas, as expected, chloroquine cured the animals at 20 mg/
kg. By day 30, the last day of the trial, all chloroquine-treated mice
were still alive and had negative blood smears for malaria
parasites. Thus, this antimalarial is significantly more active than
the tested drugs.
Discussion
Although PfLDH is not a direct chloroquine target, experimental
data have shown that this enzyme binds to chloroquine [10], [12].
Based on this information, we studied 50 commercially available
compounds as candidates to PfLDH inhibitors. The compounds
that presented the closest binding energy values to NADH, which
we considered to be the best results, were itraconazole, atorvastatin
and posaconazole. In our software simulation, these compounds
also interacted with the residues present in the PfLDH active site,
suggesting a competitive inhibition with NADH. The selected
compounds also presented strong stability inside the PfLDH active
site; thus, they could also dock in the NADH binding pocket of
PfLDH. This theoretical hypothesis proved correct in light of our
experimental data from in vitro assays performed with P. falciparum.
Indeed, the selected compounds, itraconazole, atorvastatin and
posaconazole, were all active in vitro. The results with two different
tests were similar: one used monoclonals specific to a P. falciparum
parasite protein (HRP2) and the other used monoclonals against the
PfLHD enzyme.
Posaconazole, an inhibitor of ergosterol biosynthesis [15], was
the most active compound against P. falciparum; it also was the most
effective compound against murine malaria caused by P. berghei.
Because posaconazole was the most promising compound in vitro
and in vivo in the present antimalarial study, we conducted a
second test using higher doses of the compound, this time in the
Table 2. Docking results for atorvastatin, posaconazole and itraconazole inside PfLDH.
Drugs
MolDock Score
(kcal.mol
21)
Hbond Score
(kcal.mol
21)
Number of
H-Bonds
Residues of the NADH binding
site interacting with the ligands
NADH 2249.6 229.3 22 Asn140, His195, Val138, Phe100, Gly99, Thr97,
Gly32, Ile31, Met30, Gly29, Asp53, Ile54, Tyr85
Atorvastatin 2209.3 21.9 6 Asp53, Thr97, Gly32, Ile31, Gly99
Itraconazole 2218.5 25.0 5 Asn140, Gly29, Tyr85
Posaconazole 2201.6 26.5 8 Gly99, Gly29, Met30, Ile31, Asn140, Ser 245, Glu122
doi:10.1371/journal.pone.0021237.t002
Figure 2. H-Bonds (in green) observed for NADH and atorvastatin (in yellow) with the active site residues of Pf LDH.
doi:10.1371/journal.pone.0021237.g002
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use and confirmed its activity in mice. We hope to use this drug in
subsequent human malaria trials. In other models, the in vivo
activity of posaconazole depends on the interleukins IFN-c and IL-
12, such as in the case of Trypanosoma cruzi infections in mice [16].
Posaconazole has been considered a candidate for clinical trials in
human Chagas disease caused by this hemoprotozoan parasite
[15].
Itraconazole, acquired in tablet form and purified for the tests
described herein, also caused a strong inhibition of P. falciparum
growth in vitro; however, it was only partially active against P.
berghei malaria in mice. The fact that the animals were not treated
with the same pharmaceutical form (pellets) available for human
use may explain its failure. Alternatively, it may have not been
absorbed, may have been inactivated in the animal digestive tract
or used in an insufficient dose. These possibilities should be further
explored.
Atorvastatin, despite being over 100-fold less active than
chloroquine in vitro, appears to be an attractive compound for
the development of new antimalarials because its mechanism of
action involves PfLDH. In a recent work, atorvastatin activity was
tested in combination with quinine and had a synergistic activity,
enhancing antimalarial effects [17]. In addition, as recently shown,
atorvastatin was able to reverse the binding of P. falciparum infected
human erythrocytes (cytoadherence) to endothelial cells in vitro
[18]. This drug is likely to become a good candidate for the
treatment of severe malaria, specially if used together with other
antimalarials. However, the ideal drug combinations and doses for
human use are yet to be defined, either for ACT or with another
antimalarial.
Itraconazole, like posaconazole and atorvastatin, does not
require further testing for human toxicology and bioavailability
because it is already approved and available for human use
worldwide. Itraconazole is used against fungal infections and
atorvastatin is the main component of the medicine LipitorH,
which is widely used to reduce cholesterol levels. Whether they can
be useful for malaria treatment will depend on their possible
synergisms with other antimalarials because only drug combina-
tion therapy is recommended for the control of malaria to avoid
further selection for drug resistance. It would be desirable to
perform further tests with the three compounds, applying them in
different treatment routes and in ACT.
The Plasmodium lactate dehydrogenase (pLDH) enzymes found
in all four species of human malaria parasites have been cloned,
expressed and analyzed for structural and kinetic properties that
may be explored for drug development. The pLDH from the
species P. vivax, P. malariae and P. ovale exhibit 90–92% identity to
PfLDH. The catalytic residues and the cofactor sites are similar in
the pLDH from P. falciparum and P. malariae, and the pLDH from
P. vivax and P. ovale share one substitution. Homology modeling of
the pLDH from P. vivax, P. ovale and P. malariae using the crystal
structure of PfLDH as a template yielded similar structures [19].
Thus, it would be desirable to have new anti-pLDH drugs that
are effective against major species of human Plasmodium because
cases of chloroquine-resistant P. vivax have already been reported
[3], [20]. In addition, except for the catalytic residues (Arg171,
Arg109, and the dyad His195/Asp168), PfLDH has different
active sites and substrate specificity loop residues than the human
LDH isoforms (hLDH), reflecting a relative displacement of the
nicotinamide ring and a volume increase of the active site
compared with PfLDH; PfLDH displays kinetic differences with
hLDH, suggesting that PfLDH is a unique antimalarial target
[19].
Table 3. In vitro activity of atorvastatin, itraconazole,
posaconazole and chloroquine against P. falciparum as
evaluated through their 50% inhibitory concentration (IC50)i n
immunoenzymatic assays (ELISA) performed with monoclonal
antibodies against a parasite protein (PfHRP2) or the enzyme
lactate dehydrogenase (PfLDH).
Drugs IC50 (mM) Mean ± SD in ELISA tests and CQ ratio
*
Anti-Pf LDH
CQ activity
ratio
** Anti-HRP2
CQ activity
ratio
**
Atorvastatin 13.164.5 262 13.863.2 115
Itraconazole 9.360.8 186 9.261.6 77
Posaconazole 2.660.3 52 5.361.8 44
Chloroquine-CQ 0.0560 - 0.1260.09 -
*Average of 4 experiments.
**Ratio of chloroquine activity, significantly higher that of test compounds.
doi:10.1371/journal.pone.0021237.t003
Figure 3. H-bonds (in green) observed for Itraconazole and Posaconazole (in yellow) with the active site residues of Pf LDH.
doi:10.1371/journal.pone.0021237.g003
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inhibition by the different compounds results from drug
competition with NADH for the PfLDH and that different
methods used to measure drug activity against P. falciparum in vitro
were equally efficient. The activity of itraconazole, atorvastatin
and posaconazole, selected through docking studies and confirmed
in biological assays, indicates that docking is an appropriate
strategy for antimalarial discovery; furthermore, this technique is
likely to be less expensive that traditional screening methods,
especially because these compounds are commercially available
and approved for human use. The best association(s) between
these compounds and other antimalarials remains to be deter-
mined. Further improvements in the structures of the lead
compounds could include additional pharmacophoric groups that
can interact with more amino acids of the NADH pocket, leading
to new and more effective antimalarials. Dynamic studies of these
drugs binding with PfLDH using more accurate methods can be
used to evaluate the interactions between these drugs and the
enzyme.
Materials and Methods
Molecular docking
The 3D structures of the PfLDH complex with NADH and the
substrate oxamate were obtained from the Protein Data Bank
(PDB ID: 1LDG) [21]. For the docking studies, 50 compounds
from DrugBank [13], all structural analogs of NADH, were
selected using the search algorithm of the website and accessing
the NADH chart in DrugBank through the option ‘‘show similar
structures.’’ This option uses a locally developed simplified
molecular input line entry specification (SMILES) string compar-
ison method to identify related structures and perform structure
similarity searches. All structures are converted into SMILES
strings, and a substring-matching program (similar to BLAST) is
used to identify similar structures. The scoring scheme is based
simply on the number of character matches for the longest
matching substring [13]. The selected compounds were submitted
to docking studies using MVDH [14]. The candidates with the best
conformational and energetic results were selected for further
experimental tests. MVDH [14] was used to calculate the
interaction energies between ligands and macromolecular systems
from the 3D structures of the protein and ligands. The algorithm
used was the MolDock Score, an adaptation of the Differential
Evolution (DE) algorithm [14]; the MolDock Score energy, Escore,
is defined by Equation 1, where Einter is the ligand-protein
interaction energy and Eintra is the internal energy of the ligand.
Einter is calculated according to Equation 2.
Escore~EinterzEintra ð1Þ
Einter~
X
i~ligant
X
j~protein
½EPLP(rij)z332:0
qiqj
4r2
ij
 ð 2Þ
The EPLP term is a ‘‘piecewise linear potential’’ [22] that uses
two different parameters, one for the approximation of the steric
term (van der Waals) between atoms and another for the potential
for hydrogen bonds; it describes the electrostatic interactions
between charged atoms [14]. Eintra is calculated according to
Equation 3.
Eintra~
X
i~ligant
X
j~protein
½EPLP(rij) z
X
flexiblebonds
A½1{cos(mh{ho) zEclash
ð3Þ
The first term in Equation 3 calculates all the energies involving
pairs of atoms of the ligand, except those connected by two bonds.
The second term represents the torsional energy, where h is the
torsional angle of the bond. The average of the torsional energy
bond contributions is used if several torsions can be determined.
The last term, Eclash, assigns a penalty of 1,000 kcal?mol
21 if the
distance between two heavy atoms (more than two bonds apart) is
smaller than 2.0 A ˚, ignoring infeasible ligand conformations [14].
Drug samples for pharmacological tests
Itraconazole [(2R,4S)-rel-1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-
(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-lmethyl)-1,3-dioxolan-
4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,
2,4-triazol-5-one], which is commercially available as a generic
>compound (SporanoxH, Janssen-Cilag) and is produced by
Brainfarma, was purified into the crystallized form as previously
described [23]. Atorvastatin [(3R,5R)-7-[2-(4-fluorophenyl)-3-
phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,
5-dihydroxyheptanoic acid] was provided by Farmanguinhos-
FIOCRUZ as a purified compound. Posaconazole [4-(4-(4-(4-
(((3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-
yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2s,3s)-2-hydroxypentan-
3-yl)-1,2,4-triazol-3-one] was a kind gift from the Laboratory of
Molecular Parasitology-FIOCRUZ, Belo Horizonte/MG, Brazil,
where the compound has been studied against T. cruzi [16]. A second
sample was later acquired in a drug store in USA to repeat the tests as
Posaconazole oral suspension (NoxafilH) 200 mg/5 mL, Lot #
001R5H (Schering-Plough Research Institute, Kenilwort, New
Jersey, USA).
All test drugs were assayed against P. falciparum diluted in
dimethyl sulfoxide (DMSO 0.02% v/v) (Sigma-Aldrich, St. Louis,
MO, EUA) from a 10 mg/mL stock solution and further diluted
with RPMI 1640 (Sigma-Aldrich) supplemented with Hepes
Table 4. Inhibition of P. berghei growth in mice infected with
blood parasites that were then treated orally with
atorvastatin, itraconazole, posaconazole or and chloroquine
for three consecutive days in two independent experiments.
Drugs Dose (mg/kg) % Parasitemia Reduction
*
Activity
Exp. 1 Exp.2
**
Atorvastatin 20 41 40 Yes
Itraconazole 20 30 ND Partial
Posaconazole 20 46 ND Yes
50 ND 45 Yes
100 ND 71 Yes
Chloroquine 20 100 100 Yes
ND=not done.
*Reduction of parasitemia at day five of the experiment in relation to untreated
controls (n=4 to 6 mice per group).
**In the second experiment, posaconazole was diluted from a commercial oral
suspension (NoxafilH).
Only the chloroquine-treated mice survived to day 30 post-inoculation; all the
other mice died, despite the suppression of parasitemia in relation to the
control mice.
doi:10.1371/journal.pone.0021237.t004
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Aldrich), glucose 11 mM (Sigma-Aldrich), glutamine 2% (Sigma-
Aldrich) and gentamicin 40 mg/mL (Schering-Plough, Kenilworth,
New Jersey, EUA). For each test well, the controls consisted of the
parasite in culture without drug addition or with chloroquine at
various concentrations.
Continuous cultures of P. falciparum
The chloroquine-resistant and mefloquine-sensitive P. falciparum
W2 clone [24] was maintained in continuous culture at 37uCi n
human erythrocytes (A
+) in Petri dishes (Corning, Santa Clara,
CA, USA) using the candle jar method [25] and grown in
complete medium (RPMI 1640 supplemented with 10% human
sera blood group A
+), with daily medium changes. Parasite
samples were also stored frozen in liquid nitrogen.
Antimalarial tests in vitro against blood stages of P.
falciparum
The effect of the test drugs against P. falciparum was determined
from curves of inhibition of parasite growth in vitro as described
previously [26] with some modifications [27]. Before the tests, the
ring-stage parasites were concentrated in sorbitol-synchronized
blood [28] and the suspension of infected red blood cells (iRBC)
was adjusted for parasitemia and hematocrit following the
specifications for each test; parasites were then distributed
(180 mL/well) into a 96-well microtiter plate (Corning, Santa
Clara, CA, EUA). All compounds were tested in triplicate for each
dose in parallel with chloroquine, the standard antimalarial. The
antiplasmodial activity was then measured using: (i) an ELISA
anti-HRP2 test as previously described [29] and (ii) an ELISA
anti-PfLDH (double-site enzyme-linked lactate dehydrogenase assay) [30].
The effect of antimalarial drugs is initially characterized by the
inhibition of parasite growth in drug-exposed cultures in
comparison to a drug-free control culture. When performed using
serial drug dilutions, sigmoid dose-response curves are generated
and enable the determination of the 50% inhibitory concentration
(IC50).
ELISA anti-HRP2
The production of HRP2, a histidine- and alanine-rich protein,
by P. falciparum parasites was tested in vitro as described previously
[29]. Briefly, a suspension of iRBC with sorbitol-synchronized
parasites, was adjusted to 0.05% parasitemia and 1.5% hemato-
crit, placed in 96-well plates containing the test and control drugs
at various concentrations and incubated for 72 h under the culture
conditions described above. After 24 h, the contents of the six
control wells (parasites in drug-free medium) were harvested in
microtubes and frozen for later use to further exclude the
background value (i.e., the production of HRP2 during the first
24 h of incubation) by subtracting the average value obtained from
these wells from the wells with the test and control drugs. After
72 h of incubation, the plates were frozen and thawed twice to lyse
the erythrocytes.
To perform the test, a clean plate (Maxysorp, Nunc, Denmark)
was first coated with 100 mL of the primary antibody anti-HRP2
(MPFM ICLLAB-55AH, USA) at 1.0 mg/mL. Following overnight
incubation at 4uC, the monoclonal was discarded and replaced
with 200 mL/well of the blocking solution PBS-BSA 2%
(Phosphate Buffered Saline and Bovine Serum Albumin) (Sigma-
Aldrich). Following a new incubation at room temperature for 2 h,
the plate was washed three times with PBS/Tween20 at 0.05%
(PBS-T). Then, each pretreated well received 100 mLo fP.
falciparum parasite culture (as described above), which was
prehemolyzed by freeze-thawing at 270uC. In each test, two
hemolyzed control sets of six wells each were used; one containing
the 24 h cultures (background), the other with the 72 h parasite
cultures. After incubation for 1 h at room temperature, the plate
was again washed three times with PBS-T, incubated with
100 mL/well of the secondary antibody (MPFG55P ICLLABH,
USA), diluted 1:5,000 times, and again incubated for 1 h at room
temperature. After three more washes with PBS-T, each well
received 100 mL of 3,39,5,59-Tetramethylbenzidine (TMB) chro-
mogen (KPL, Gaithersburg, MD, EUA) and was incubated for
10 min at room temperature in the dark; the reaction was stopped
with 50 mL/L of 1 M sulfuric acid and the absorbance was
immediately read at 450 nm in a spectrophotometer (Spectra-
Max340PC
384, Molecular Devices).
ELISA anti-PfLDH
The anti-PfLDH test was performed as described previously
[30]. Briefly, cultures of P. falciparum were adjusted to 0.5%
parasitemia and 2% hematocrit, placed in 96-well plates with the
test drugs or control antimalarial drugs at different concentrations.
The plates were then incubated under the same culture conditions
as described above for 48 h, frozen and thawed thrice to lyse
erythrocytes.
To perform the anti-PfLDH test, a clean plate was first coated
with 100 mL/well of the primary antibody anti-PfLDH (17E4
Vista Diagnostics International LLCH, USA) at 1.0 mg/mL.
Following overnight incubation at 4uC, the monoclonal was then
discarded and replaced with 300 mL/well of the blocking solution
(PBS-BSA 1%); the plate was then incubated at room temperature
for 4 h and washed four times with PBS-T. The precoated plate
received 100 mL of the P. falciparum parasite cultures in each well
(as above), which was prehemolyzed by freeze-thawing and diluted
1:100 times in PBS/BSA 1%. For each test, two hemolyzed
control sets of six wells each were used, one containing the parasite
in cultures without drug addition and the other with uninfected
red blood cells (RBCs).
The plate containing the parasite lysate and the monoclonal was
again incubated for 1 h at room temperature, washed four times
with PBS-T and then incubated with 100 mL/well of the
secondary antibody (19g7, Vista Diagnostics International LLCH,
USA) diluted 1:5,000 times. After 1 h of incubation at room
temperature and four washes with PBS-T, each well received
100 mL of streptavidin-HRP conjugate (Sigma-Aldrich) diluted
1:1,000 and incubated for 30 min at room temperature. The plate
was washed four times with PBS-T and incubated with 100 ml/
well of TMB chromogen followed by 10 min of incubation at
room temperature in the dark. The reaction was stopped with
50 mL/L of 1 M sulfuric acid and the absorbance was immediately
read at 450 nm in a spectrophotometer (SpectraMax340PC
384,
Molecular Devices).
Ethical committee approval for animal use
Methodological issues involving the use of laboratory animals in
this study were approved by the Ethics Committee for Animal
Use, the Oswaldo Cruz Foundation - Fiocruz (CEUA L-0046/08).
Antimalarial tests in mice infected with P. berghei
The antimalarial chemotherapy suppressive tests were per-
formed as previously described [31], with modifications [32]. The
P. berghei NK65 strain, a chloroquine-sensitive parasite, was stored
at 270uC and also maintained by weekly blood passages in
outbred Swiss mice. For the chemotherapy experiments, adult
female mice weighing 2062 g were inoculated intraperitoneally
with 1610
5 iRBC and kept together in a cage. Twenty-four hours
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mice per cage, and then orally treated with the test and control
compounds daily for three consecutive days. The drugs were
freshly diluted with water, DMSO 3% or RPMI and given orally
(200 mL per animal) at doses of 20–100 mg/kg. Posaconazole was
used at a dose of 20 mg/kg body weight in the first experiment
and at 50 and 100 mg/kg in the second experiment. Chloroquine-
treated and untreated control groups were included in each test.
Thin blood smears were taken starting at day five after parasite
inoculation, Giemsa stained and examined microscopically. Drug
activity was determined on the basis of the average parasitemia per
group of mice. The percent inhibition of parasite multiplication in
the treated groups was compared to the untreated controls and the
parasite inhibition growth was calculated based on the percent
parasitemia in the groups according to equation 4 [32].
Percent parasitemia~
PC{PTG
PC
x100 ð4Þ
Where: PC is the parasitemia in the control group and PTG is
the parasitemia in the test group. Drugs that reduced parasitemia
by 29–40% were considered partially active; a reduction of .40%
was considered active. Overall mortality was monitored daily until
day 30 post-infection in all groups.
Supplementary Material. A table with the energy values of
the main HBond interactions between residues of NADH binding
site and NADH, atorvastatin, itraconazole and posaconazole is
available as Table S1.
Supporting Information
Table S1 HBond Energies between residues of NADH binding
site and NADH, atorvastatin, itraconazole and posaconazole.
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